New York, June 15, 2026, 17:52 EDT
- Intellia shares were recently up about 23% at $14.92 after fresh Phase 3 data for lonvo-z in hereditary angioedema.
- The company said lonvo-z cut monthly attacks requiring on-demand treatment by 89% and moderate-to-severe attacks by 91% versus placebo. GlobeNewswire
- The next major catalyst is completion and FDA review of the rolling BLA, a biologics license application seeking U.S. approval. GlobeNewswire
Intellia Therapeutics shares surged Monday as investors reacted to additional late-stage data for lonvoguran ziclumeran, or lonvo-z, the company’s one-time CRISPR-based therapy for hereditary angioedema, a rare genetic disease that causes unpredictable and potentially life-threatening swelling attacks. The Nasdaq-listed biotech was recently trading at $14.92, up roughly 23%, with volume far above normal levels. Stocks rise when new information increases expected future sales, profits or approval odds; they fall when investors see lower odds, higher risks or dilution.
The move followed Intellia’s June 13 update from the Phase 3 HAELO trial, a late-stage human study typically used to support regulatory approval. The company said lonvo-z met the primary endpoint with an 87% reduction in mean monthly attacks versus placebo during weeks 5 to 28, while 62% of treated patients were attack-free and therapy-free over the six-month efficacy period, compared with 11% on placebo. Additional endpoints showed an 89% reduction in attacks requiring emergency on-demand treatment and a 91% reduction in moderate-to-severe attacks. Intellia CEO John Leonard said the results were the “first Phase 3 results” to show the promise of in vivo CRISPR gene editing, meaning gene editing performed inside the body rather than on cells edited outside the body. GlobeNewswire
The data matter for the stock because lonvo-z is Intellia’s clearest path to a first commercial product. The company has already started a rolling BLA with the FDA and said it still expects regulatory approval and a U.S. launch in the first half of 2027, if approved. A rolling BLA lets a company submit parts of an application over time, which can shorten the path to review for eligible therapies. The next major catalyst for NTLA investors is completion and acceptance of that filing, followed by any FDA review timeline or approval decision. GlobeNewswire
The bull case is that Intellia now has unusually strong pivotal data for a one-time therapy in a market where many patients still rely on chronic injections or pills. Leerink Partners analyst Mani Foroohar, cited by Investor’s Business Daily, called the results evidence of “clean safety and best-in-class efficacy and convenience,” while H.C. Wainwright reiterated a Buy rating and $25 price target and Citizens kept a Market Outperform rating with a $30 target after the data. Investors.com Investing.com Intellia also reported $517.2 million in cash, equivalents and marketable securities at March 31, plus about $207 million in gross proceeds from an April stock offering, with management saying existing cash can fund operations at least into 2028. Intellia Therapeutics
The bear case is that Intellia remains a clinical-stage biotech with no approved commercial product, ongoing losses and material regulatory risk. The company posted a $96.2 million first-quarter net loss, and its April financing sold 16.7 million shares at $10.75, a reminder that biotech rallies can be offset by shareholder dilution when companies raise capital. Intellia Therapeutics Intellia Therapeutics Safety also remains central to the stock story: Intellia’s separate nex-z program previously faced FDA clinical holds after liver enzyme concerns, and the company’s SEC filing says no in vivo genome-editing therapy has yet been approved in the U.S., EU or other key jurisdictions. SEC
After Monday’s jump, NTLA looks promising but still risky rather than clearly cheap for conservative investors. The attraction is real: lonvo-z has Phase 3 efficacy, supportive safety data and a defined FDA filing path. The risk is also real: approval, pricing, reimbursement, launch execution and long-term safety must still be proven, and the sharp one-day gain has already priced in some optimism. For now, the stock’s next move is likely to depend less on broad market sentiment and more on whether Intellia can turn the HAELO data into an accepted FDA application and, ultimately, an approved first product.
